Extended mirikizumab dose produces UC response in initial nonresponders

Additional, extended treatment with mirikizumab helped produce a clinical response in patients with ulcerative colitis who initially did not respond to treatment, according to study results.William J. Sandborn, MD, of the University of California, San Diego, and colleagues wrote that the drug (Lilly) has previously shown clinical efficacy in phase 2 studies of psoriasis and Crohn’s disease.“Induction regimens evaluated in most clinical trials are no more than 12 weeks, and some patients, especially those less responsive to initial induction treatment, could potentially improveRead More

Share on facebook
Share on twitter
Share on linkedin